维普期刊资源整合服务平台（V6.5）

20篇 您的检索式：作者名="Britten CD"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

	题名	作者	年代	出处	被引量
1	Oral paclitaxel and concurrent cyclosporin A : targeting clinically relevant systemic exposure to paclitaxel 显示文摘	Britten CD Baker SD Denis LJ	2000	Clin Cancer Res2000，6，9：	1
2	Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay 显示文摘	Britten CD Izbicka E Hilsenbeck S	1999	Cancer ChemotherPhamacol1999，44，2：	1
3	PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types 显示文摘	Britten CD	2013	Cancer Chemotber Pharma- col2013，71，6：	1
4	PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types 显示文摘	Britten CD	2013	Cancer Chemother Pharmacol2013，71，：	1
5	G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer 显示文摘	Bucher N Britten CD	2008	Br J Cancer2008，98，3：	1
6	A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period 显示文摘	BRITTEN CD KABBINAVAR F HECHT JR	2008	Cancer Chemother Pharmacol2008，61，3：	1
7	PI3K and MEK inhibitor combinations:examining the evidence in selected tumor types 显示文摘	Britten CD	2013	Cancer Chemother Pharma- col2013，71，6：	1
8	G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer 显示文摘	Bucher N Britten CD	2008	Br J Cancer2008，98，3：	1
9	Pharmacokinetics of oral deforolimus(AP23573,MK-8669)显示文摘	Fetterly GJ Mita MM Britten CD	2008	J Clin Oncol2008，26，14：	1
10	Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel 显示文摘	Britten CD Baker SD Denis LJ	2000	Clin Cancer Res2000，6，9：	1
11	Activity of the multitargeted antifolate LY231514 in the tumor coloning assay显示文摘	Britten CD Izbicka E Hilsenbeck S	1999	Cancer Chemother Pharmaco1999，44，2：	1
12	Activity of the multitargeted antifolate (LY 231514) in the human tumor cloning assay显示文摘	Britten CD Izbicka E Hilsenbeck S	1999	Cancer Chemotherapy Pharmacol1999，44，2：	1
13	Deforolimus trial 106: a phase 1 trial evaluating 7 regimens of oral deforolimus (AP23573,MK-8669) 显示文摘	Mita MM Britten CD Poplin E et el	2008	J Clin Oncol2008，26，：	1
14	Activity of the multitargeted antifolate(LY 231514)in the human tumor cloning assay显示文摘	Britten CD Izbicka E Hilsenbeck S	1999	Cancer Chemotherapy Pbarmacol1999，4，2：	1
15	Enhanced antitumor activity of 6-hydroxymethylacylfulvene in combination with irinotecan and 5-fluorouracil in the HT29 human colon tumor xenograft model 显示文摘	Britten CD Hilsenbeck SG Eckhardt SG et ol	1999	Cancer Bes1999，59，5：	1
16	Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay显示文摘	Britten CD Izbicka E Hilsenbeck S	1999	Cancer Chemother Pharmacol1999，44，2：	1
17	A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period显示文摘	Britten CD Kabbinavar F Hecht JR	2008	Cancer Chemother Pharmacol2008，61，3：	1
18	Enhanced antitumor activity of 5-fluorouracil in the HT29 human colon tumor xenograft model显示文摘	Britten CD Hilsenbeek SG Eckhaatt SG	1999	Cancer Res1999，59，5：	1
19	Activity of the muhitargeted an- tifolate LY231514 in the human tumor cloning assay 显示文摘	Britten CD Izbicka E Hilsenbeck S	1999	Cancer Chemother Pharmacol1999，44，2：	1
20	Deforolimus trial 106:A Phase Ⅰ trial evaluating 7 regimens of oral Deforolimus (AP23573,MK-8669)显示文摘	Mita MM Britten CD Poplin E	2008	J Clin Oncol2008，26，：	1

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示